Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

00 p.m. Pacific Time with management to discuss results from the meeting as well as financial results for the first quarter and provide a general corporate update.

About Anthera PharmaceuticalsAnthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
... , , , ... service Contract Research Organization (CRO) founded in India, today announced the ... Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial ... , "We are excited to have the rollout of ...
... Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... a New Drug Submission (NDS) with the Therapeutic Products ... the antidepressant trazodone. , "We are pleased to file ... R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. ...
Cached Medicine Technology:SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 3
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to ... Melville, New York 11747. The new facility is a state of the art ... , Richard Quadrino, the firm's CEO and founder, said, "We are pleased to service ...
(Date:7/7/2015)... ... July 07, 2015 , ... Safe Catch is setting revolutionary purity limits ... Albertsons, Gelson’s Markets, New Leaf Community Markets, Sprouts Farmers Market and Wegmans are some ... technology to test every fish for mercury,” said Safe Catch co-founder Sean Wittenberg. “We ...
(Date:7/7/2015)... ... ... Parents and guardians of teenagers or young adults will be interested in reading ... drug and alcohol abuse located in Southwest Michigan. A recently released study by New ... in the “club drug” use among high school seniors. The blog post offers guidance ...
(Date:7/7/2015)... CA (PRWEB) , ... July 07, 2015 , ... ... promotion on teeth whitening treatments. A professional teeth whitening is one of the fastest, ... appearance, as well as they can decrease smile satisfaction and confidence. With the right ...
(Date:7/7/2015)... and Wellesley, MA (PRWEB) , ... July 07, ... ... National Institute of Whole Health (NIWH) have jointly announced a partnership focused ... addressing unsolved, chronic medical case studies. The study will be conducted with NIWH ...
Breaking Medicine News(10 mins):Health News:Safe Catch Launches Tuna with Lowest Mercury Limit of Any Brand 2Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 2Health News:Isabel Healthcare and the National Institute of Whole Health Announce Partnership for a Pilot Study Using the Isabel Diagnostic Support Tool and Knowledge Organizer 3
... School of Medicine indicates that CT scans are more effective ... cancers in their most treatable stages. The data, published online ... lung cancers found through annual CT screening are similar to ... growth rates and cell-type distribution. In fact, the report showed ...
... benefit from better training and testing of health professionals as ... Learning and Simulation (CAMLS) in downtown Tampa. Packed with ... CAMLS is expected to draw 30,000 health professionals from around ... in interdisciplinary teams, and to have their skills evaluated by ...
... -- There appears to be a link between the common ... a new study suggests. In people with obstructive sleep ... the upper airway during sleep. This results in pauses in ... snoring. In the new study, U.S. Centers for Disease ...
... Institute on Asian Consumer Insight (ACI) announced its strategy and ... to grow their business in Asia. Top on ... Financial Times. Modelled in format after the World Economic Forum ... leaders, will be a platform to examine Asian consumers. ...
... 2.2 million people in the United States live with epilepsy, ... seizures. The highest rate of onset occurs in children ... and socio-economic backgrounds, yet this common disorder is widely misunderstood. ... that vary in type, cause, severity, and frequency. Many ...
... children in the United States has an autism spectrum disorder. ... Thursday (March 29) that looked at data gathered in 2008 from ... data show that autism rates in the U.S. are higher than ... were diagnosed with autism or a related disorder. The latest figures ...
Cached Medicine News:Health News:Lung cancers detected by CT screening grow as fast as those found with traditional methods 2Health News:Lung cancers detected by CT screening grow as fast as those found with traditional methods 3Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 2Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 3Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 4Health News:National institute launched to help businesses grow with Asian consumers 2Health News:National institute launched to help businesses grow with Asian consumers 3Health News:National institute launched to help businesses grow with Asian consumers 4Health News:National institute launched to help businesses grow with Asian consumers 5Health News:IOM report identifies public health actions for improving the lives of those with epilepsy 2
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... powder reagent once reconstituted offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
LCD chart display...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: